Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.52 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.52 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 7/20 | 0.49 |
| ▸ | DHFR | P00374 | 4/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | FPGS | Q05932 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496967 | 0.80 | IP6K1 (0.65) | SLC2A1IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL2699051 | 0.77 | KDM4E (0.50) | IP6K1ACVR1 | |
| SCHEMBL2699340 | 0.76 | MAP4K4 (0.55) | — | |
| SCHEMBL22980875 | 0.75 | IP6K1 (0.66) | SLC2A1IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL2700897 | 0.74 | ECE2 (0.50) | — | |
| SCHEMBL7427860 | 0.73 | IP6K1 (0.68) | SLC2A1IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL8170598 | 0.73 | IP6K1 (0.71) | SLC2A1IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL2698516 | 0.72 | EGFR (0.39) | PARP1 | |
| SCHEMBL22042406 | 0.72 | IP6K1 (0.61) | SLC2A1IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL20334906 | 0.72 | IP6K1 (0.61) | SLC2A1IP6K1IP6K3IP6K2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3093289-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | Amgen, Inc (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2081931-B1 | [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor | AMGEN INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2578583-A1 | Fused heterocyclic derivatives and methods of use | Amgen Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-101528743-B | Fused heterocyclic derivatives and methods of use | AMGEN INC | 2013-02-06 | — | — | CN | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8212041-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| CN-101528743-A | Fused heterocyclic derivatives and methods of use | AMGEN INC (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-2081931-A2 | FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | Amgen Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2008008539-A2 | FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | AMGEN INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | SLC2A1 1405/4885IP6K1 3165/4885IP6K3 3105/4885 |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | SLC2A1 1405/4885IP6K1 3165/4885IP6K3 3105/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | SLC2A1 1405/4885IP6K1 3165/4885IP6K3 3105/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | SLC2A1 1405/4885IP6K1 3165/4885IP6K3 3105/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | SLC2A1 1405/4885IP6K1 3165/4885IP6K3 3105/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | SLC2A1 1405/4885IP6K1 3165/4885IP6K3 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.